Molecule
Trientine tetrahydrochloride is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. It is available as tablets for oral use. MedsAcross supplies Trientine tetrahydrochloride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CUVRIOR is indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine.
Source: US FDA prescribing information
Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine also chelates copper in the intestinal tract, reducing copper absorption.
Source: US FDA prescribing information
Recommended Dosage and Administration Starting total daily dosage of CUVRIOR in adults is 300 mg up to 3,000 mg orally in divided doses (2 times daily). See full prescribing information for recommended conversion table when switching from penicillamine to CUVRIOR. Total daily dosage of CUVRIOR should not exceed 3,000 mg. If the number of CUVRIOR tablets prescribed per day cannot be equally divided among doses, then divide total daily dosage such that the higher number of tablets is taken with the first daily dose. Take CUVRIOR on an empty stomach. Swallow tablets without crushing, chewing, or dissolving tablets. Switching from Other Trientine Products CUVRIOR is not substitutable on a milligram-per-milligram basis with other trientine products. See full prescribing information for additional information on switching from other trientine products.
Source: US FDA prescribing information
CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR. Hypersensitivity to trientine or to any of the excipients in CUVRIOR.
Source: US FDA prescribing information
Potential for Worsening of Clinical Symptoms at Initiation of Therapy: May include neurological deterioration. Adjust dosage or discontinue CUVRIOR if clinical condition worsens. Copper Deficiency: Periodic monitoring is required. Iron Deficiency: If iron deficiency develops, a short course of iron supplementation may be given. Hypersensitivity Reactions: If rash or other hypersensitivity reaction occurs, consider discontinuing CUVRIOR.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Potential for Worsening of Clinical Symptoms at Initiation of Therapy Copper Deficiency Iron Deficiency Hypersensitivity Reactions Most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings.
Source: US FDA prescribing information
Mineral Supplements (e.g. iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable: Iron: Take CUVRIOR at least 2 hours before or 2 hours after iron. Other Mineral Supplements: Take CUVRIOR at least 1 hour before or 2 hours after other mineral supplements. Other Drugs for Oral Administration: Take CUVRIOR at least 1 hour apart from any other oral drug.
Source: US FDA prescribing information
Store at a controlled room temperature of 20°C to 25°C (68°F to 77°F), excursions between 15°C and 30°C (59°F and 86°F) are permitted.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Trientine tetrahydrochloride, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cuvrior 300 mg tabletOral | Orphalan | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 April 2022 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Trientine tetrahydrochloride and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Trientine tetrahydrochloride, including Cuvrior.
Yes. The US FDA first approved Trientine tetrahydrochloride on 28 April 2022, according to Drugs@FDA.
No listed presentation of Trientine tetrahydrochloride is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.